• Difloxacin HCl: Quinolone Antimicrobial Antibiotic in Bench

  2026-06-13

  Difloxacin HCl stands out for its dual role in both antimicrobial susceptibility testing and multidrug resistance reversal, making it indispensable for translational research. This guide translates experimental protocols, troubleshooting tips, and new mechanistic insights into actionable steps for microbiology and oncology labs.

• Mubritinib-HSA Binding: Mechanistic Insights for Drug Delive

  2026-06-12

  This article examines the molecular recognition mechanisms between the mitochondrial electron transport chain inhibitor mubritinib and human serum albumin (HSA), as elucidated by a recent multispectroscopic and docking study. These findings inform the broader pharmacological understanding of drug-protein interactions, with direct implications for the design and optimization of anti-proliferative agents in cancer therapy.

• Ionophore Toxicity Mechanisms and Tiamulin Interactions in A

  2026-06-12

  This review synthesizes advances in understanding the clinical and molecular mechanisms of ionophore toxicity in animals, emphasizing the complex interplay between ionophore pharmacology and veterinary drug interactions. The inclusion of Tiamulin’s modulatory effects on ionophore biotransformation provides actionable insights for researchers studying drug safety and efficacy in veterinary settings.

• Merimepodib (VX-497): IMPDH Inhibition in Antiviral and Immu

  2026-06-11

  Merimepodib (VX-497) stands out as a selective, reversible, and orally bioavailable IMPDH inhibitor, enabling precise dissection of nucleotide metabolism across oncology, virology, and immunology. Its robust antiviral and immunosuppressive profiles—now extended by recent PEDV mechanistic insights—make it a pivotal tool for host-directed therapeutic research.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-06-11

  Wang et al. elucidate the METTL16-SENP3-LTF axis as a key driver of ferroptosis resistance and tumorigenesis in hepatocellular carcinoma. The study provides mechanistic insights into RNA methylation’s role in iron metabolism and highlights potential molecular targets for sensitizing HCC to ferroptosis-based therapies.

• Tiamulin (Thiamutilin): Ribosomal Targeting and Resistance I

  2026-06-10

  Explore how Tiamulin (Thiamutilin) disrupts bacterial protein synthesis at the ribosomal level and the clinical implications of resistance mutations. This article uniquely bridges structural, pharmacokinetic, and translational perspectives for veterinary and emerging anti-inflammatory applications.

• Tiamulin (Thiamutilin): Optimized Protocols for Veterinary a

  2026-06-10

  Tiamulin (Thiamutilin) stands out for its precise dual action as a veterinary antibiotic and anti-inflammatory agent, uniquely targeting both infectious and inflammatory pathways in pigs, poultry, and cellular models. This article delivers actionable, evidence-based workflows and troubleshooting strategies to help researchers and veterinarians maximize APExBIO's trusted SKU BA1083 across diverse experimental contexts.

• SN-38 Inhibits FUBP1-DNA Binding and Topoisomerase I in Canc

  2026-06-09

  This study demonstrates that 7-Ethyl-10-hydroxycamptothecin (SN-38) and camptothecin, beyond their established topoisomerase I inhibition, disrupt the binding of the oncogenic regulator FUBP1 to its DNA target FUSE. These findings reveal a dual mechanism with implications for advanced colon and liver cancer research, particularly in tumors overexpressing FUBP1.

• MHY1485: mTOR Activator Workflows for Autophagy & Follicle S

  2026-06-09

  MHY1485 is a potent mTOR activator and autophagy inhibitor, enabling precise modulation of the mTOR signaling pathway in cell biology and ovarian follicle research. This article delivers actionable protocol enhancements, troubleshooting strategies, and cross-study insights that set MHY1485 apart for advanced experimental needs.

• Doxorubicin (SKU A3966): Reliable Solutions for Cancer Assay

  2026-06-08

  This article addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays, highlighting how Doxorubicin (SKU A3966) from APExBIO delivers reproducibility and data-backed performance. Scenario-driven Q&As guide researchers through experimental design, protocol optimization, and product selection, always with a focus on validated parameters and workflow integrity.

• Zosuquidar (LY335979): Workflow Advances in MDR Cancer Resea

  2026-06-08

  Zosuquidar (LY335979) 3HCl empowers researchers to directly tackle multidrug resistance by selectively inhibiting P-glycoprotein efflux. This article delivers actionable protocols, troubleshooting expertise, and translational insights for maximizing experimental sensitivity in cancer models.

• ATR-Mediated DNA Damage and Apoptosis Induced by 5-Azacytidi

  2026-06-07

  This study demonstrates that 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses and promotes apoptosis in both drug-sensitive and drug-resistant multiple myeloma cells. The findings highlight its potential for enhancing cytotoxicity when combined with doxorubicin or bortezomib, supporting new therapeutic strategies for resistant myeloma.

• PBS (Phosphate-Buffered Saline): Parameters and Lab Workflow

  2026-06-06

  PBS (Phosphate-Buffered Saline, SKU K2818) is a sterile, isotonic buffer formulated for routine laboratory procedures such as cell washing and dilution, where precise pH and osmolarity control are required. It should be reserved strictly for in vitro research and is not suitable for diagnostic or clinical use.

• Doxorubicin (Adriamycin): Applied Cancer Research Workflows

  2026-06-05

  Doxorubicin (Adriamycin) is a gold-standard chemotherapeutic for dissecting DNA damage and apoptosis in both solid tumors and hematologic malignancy research. This guide delivers workflow enhancements, troubleshooting strategies, and practical protocol tips to maximize reproducibility and insight in cancer biology studies leveraging APExBIO’s trusted Doxorubicin.

• Doxorubicin in Cancer Research: Protocols, Innovation, and T

  2026-06-05

  Doxorubicin (Adriamycin) remains a gold-standard chemotherapeutic agent in translational cancer research, enabling precise modeling of DNA damage and apoptosis induction. This article delivers cutting-edge workflow enhancements, reference-backed troubleshooting, and actionable insights for maximizing the compound’s impact in solid tumor and hematologic malignancy assays.

15112 records 1/1008 page Next 12345 下5页 Last page